Search

Search Results

• 

  Preface to the 13^th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026

  Anna Falanga, Benjamin Brenner, Alok A. Khorana

  16-04-2026

  https://doi.org/10.4081/btvb.2026.479

  0

  PDF: 0
• 

  PO45 | KHORANA RISK SCORE AND GENOMIC PROFILING FOR PREDICTION OF VENOUS THROMBOEMBOLISM IN OVARIAN CANCER P. Santini, L. Mastrantoni, G. Anderson, F. Camarda, I. Marino, J. Preziosi, M. Buttarelli, M. Manfredelli, A. Minucci, F. Persiani, L. Giacò, T. Pasciuto, I. Conti, I. Mozzetta, F. Mancinetti, S. M. P. D’Ambrosio, M. Bigossi, C. Marchetti, V. Salutari, G. Scambia, C. Nero, R. Pola | Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.539

  1

  PDF: 0
• 

  PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD J. Barker¹, K. Libby¹, C. Holmes², K. Martin² | ¹University of Vermont Health System; ²Department of Medicine, University of Vermont, Burlington, VT, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.541

  2

  PDF: 0
• 

  PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508^CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker¹, M. P. O’Brien², M. Carrier³, J. Connors⁴, A. Falanga⁵, A. Manzano⁶, R. Mcbane⁷, Y.Y. Janjigian¹, G. O’Kane⁸, M. Onisko², J. Kaplan², A.P. Kithcart², D.E. Gutstein², A. Khorana⁹, M. F. Walsh² | ¹Memorial Sloan Kettering Cancer Center, New York, USA; ²Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; ³University of Ottawa, Ottawa, ON, Canada; ⁴Harvard Medical School, Boston, MA, USA; ⁵Hospital Papa Giovanni XXIII, Bergamo, Italy; ⁶Hospital Universitario 12 de Octubre, Madrid, Spain; ⁷Mayo Clinic, Rochester, MN, USA; ⁸St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; ⁹James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.545

  2

  PDF: 0
• 

  PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione¹, G. Gini¹, S. Rupoli¹, A. Poloni^1|2 | ¹Hematology, AOU delle Marche, Ancona; ²Università Politecnica delle Marche, Ancona, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.527

  1

  PDF: 0
• 

  PO38 | PERICATHETER AND SYSTEMIC THROMBOSIS DURING CAR-T LYMPHOCYTAPHERESIS: INCIDENCE AND CLINICAL CORRELATES I. Pansini^1|2, E. Galli¹, A. Corrente², N. Piccirillo^1|2, M. Viscovo^1|2, S. Hohaus^1|2, P. Chiusolo^1|2, F. Sorà^1|2, S. Sica^1|2 | ¹Department of Laboratory and Hematologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; ²Hematology Section, Department of Radiologic and Hematologic Sciences, Università Cattolica del Sacro Cuore, Rome, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.532

  0

  PDF: 0
• 

  Factor XI inhibitors in cancer-associated venous thromboembolism: what’s next?

  Hiranya M. Dave, Mehrie H. Patel, Keith R. McCrae, Alok A. Khorana

  16-04-2026

  https://doi.org/10.4081/btvb.2026.424

  0

  PDF: 0
• 

  Unlocking the potential of statins for venous thromboembolism prophylaxis in cancer: why conduct the STAT-CAT trial?

  Jean M. Connors, Robert J. Glynn, Alok A. Khorana, Paul M. Ridker

  16-04-2026

  https://doi.org/10.4081/btvb.2026.450

  0

  PDF: 0